BridgeBio Oncology Therapeutics (BBOT) Profit After Tax (2024 - 2026)

BridgeBio Oncology Therapeutics has reported Profit After Tax for 3 years, with the latest figure at -$42.1 million in Q1 2026.

• Quarterly Profit After Tax fell 90.52% year-over-year to -$42.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$154.1 million (down 90.29% YoY) and the FY2025 annual result came in at -$134.0 million, down 80.35% from the prior year.
• Profit After Tax fell to -$42.1 million in Q1 2026 per BBOT's latest filing, from -$38.8 million in the prior quarter.
• Over five years, Profit After Tax peaked at -$15.4 million in Q1 2024 and troughed at -$44.8 million in Q3 2025.
• A 3-year average of -$27.8 million and a median of -$22.1 million in 2025 frame the typical range for Profit After Tax.
• The widest YoY moves for Profit After Tax: up 30.3% in 2025, down 158.37% in 2025.
• Over 3 years, Profit After Tax stood at -$19.7 million in 2024, then tumbled by 96.6% to -$38.8 million in 2025, then retreated by 8.65% to -$42.1 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$42.1 million, -$38.8 million, and -$44.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.